Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Weight changes with depot neuroleptic maintenance therapy.

D A Johnson, M Breen

    Acta Psychiatrica Scandinavica
    |May 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Donepezil treatment restores the ability of estradiol to enhance cognitive performance in aged rats: evidence for the cholinergic basis of the critical period hypothesis.

    Hormones and behavior·2009
    Same author

    Virtual enriched environments in paediatric neuropsychological rehabilitation following traumatic brain injury: Feasibility, benefits and challenges.

    Developmental neurorehabilitation·2009
    Same author

    Salivary secretion, mucin concentrations and Candida carriage in HIV-infected patients.

    Oral diseases·2009
    Same author

    High genetic diversity, phenotypic uniformity, and evidence of outcrossing in sclerotinia sclerotiorum in the columbia basin of washington state.

    Phytopathology·2008
    Same author

    Competitive Fitness of Phytophthora infestans Isolates Under Semiarid Field Conditions.

    Phytopathology·2008
    Same author

    Aggressiveness of Isolates of Phytophthora infestans from the Columbia Basin of Washington and Oregon.

    Phytopathology·2008
    Same journal

    Developmental Trauma as a Prognostic Factor for Later Psychotic Disorder in an Adolescent Clinical Cohort: A 20-Year Follow Up Study.

    Acta psychiatrica Scandinavica·2026
    Same journal

    The Prevalence of Obstructive Sleep Apnoea in Schizophrenia, Bipolar Disorder and Major Depressive Disorder: A Systematic Review With Meta-Analysis.

    Acta psychiatrica Scandinavica·2026
    Same journal

    Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024.

    Acta psychiatrica Scandinavica·2026
    Same journal

    Benzodiazepine Use and Mortality Risk: A Nationwide Cohort Study on New Benzodiazepine Users With a 5-Year Follow-Up.

    Acta psychiatrica Scandinavica·2026
    Same journal

    Leveraging Family Genetic Risk Scores to Understand the Etiology of Suicidal Behaviors and Their Associations With Psychiatric Disorders.

    Acta psychiatrica Scandinavica·2026
    Same journal

    Does the Loss of Autobiographical Memories Contribute to the Therapeutic Effect of Electroconvulsive Therapy?

    Acta psychiatrica Scandinavica·2026
    See all related articles

    Injectable antipsychotics for schizophrenia maintenance therapy caused significant weight gain in 55% of patients. Monitoring weight and diet advice are crucial for managing this side effect in chronic schizophrenia treatment.

    Area of Science:

    • Psychiatry
    • Pharmacology
    • Clinical Medicine

    Background:

    • Schizophrenia requires long-term maintenance therapy, often involving injectable antipsychotics.
    • Weight gain is a known side effect of antipsychotic medications, impacting patient health and adherence.

    Purpose of the Study:

    • To assess the incidence of clinically significant weight gain in schizophrenic patients on injectable depot neuroleptic maintenance therapy.
    • To investigate potential differences in weight gain between specific neuroleptics and influencing factors.

    Main Methods:

    • Prospective study design.
    • Inclusion of patients with schizophrenia receiving injectable depot neuroleptic maintenance therapy.
    • Monitoring of weight changes over time, with analysis of drug type, dose, and concurrent anti-parkinsonian medication use.

    Related Experiment Videos

    Main Results:

    • 55% of patients experienced clinically significant weight gain.
    • No significant difference in weight gain was observed between flupenthixol decanoate and fluphenazine decanoate.
    • Weight gain did not show a meaningful relationship with drug dose or the use of anti-parkinsonian drugs.
    • Weight gain persisted for at least 2 years, even after a mental state relapse.

    Conclusions:

    • Injectable depot neuroleptics are associated with substantial weight gain in schizophrenia maintenance therapy.
    • Continuous monitoring of patient weight and provision of dietary guidance are essential components of managing chronic schizophrenia.
    • Proactive management strategies are needed to mitigate long-term weight gain associated with antipsychotic treatment.